New treatment option for schizophrenia Reagila(R) listed on PBS
New treatment option for schizophrenia Reagila(R) listed on PBS

MELBOURNE, Sep 6, 2021 – (ACN Newswire via SEAPRWire.com) – A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for... » read more

New treatment option for schizophrenia – Reagila(R) – listed on PBS this week
New treatment option for schizophrenia – Reagila(R) – listed on PBS this week

– Adults living with schizophrenia will have access to a new treatment option with Reagila(R) (cariprazine) now reimbursed on the Pharmaceutical Benefits Scheme from 1 September, 2021.1 – There continues to be a significant, unmet need in treating schizophrenia. With a complex range of symptoms,2 treatment is not a “one size fits all”.3 This listing... » read more